Opus Genetics (IRD) Other Non-Current Liabilities (2010 - 2026)
Opus Genetics (IRD) posted quarterly Other Non-Current Liabilities of $77.3 million for Q1 2026, up 197.67% quarter-over-quarter from $26.0 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Other Non-Current Liabilities for 14 consecutive years, with $77.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $77.3 million; the TTM figure through Mar 2026 stood at $77.3 million (changed N/A YoY), while the FY2025 annual figure was $26.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $77.3 million in Q1 2026 per IRD's latest filing, from $26.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $77.3 million in Q1 2026 and bottomed at $25000.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $20.7 million across 3 years, with a median of $93000.0 in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 62.15 Mn |
| Mar 31, 2026 | 77.35 Mn |
| Dec 31, 2025 | 25.99 Mn |
| Sep 30, 2025 | 21.33 Mn |
| Jun 30, 2025 | 14.70 Mn |
| Mar 31, 2025 | 14.70 Mn |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 93,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Dec 31, 2020 | 27.96 Mn |
| Sep 30, 2020 | 110,781.00 |
| Jun 30, 2020 | 268,811.00 |
| Mar 31, 2020 | 100,109.00 |
| Sep 30, 2019 | 123,872.00 |
| Jun 30, 2019 | 366,732.00 |
| Mar 31, 2019 | 794,215.00 |
| Dec 31, 2018 | 2.31 Mn |
| Sep 30, 2018 | 4.10 Mn |
| Jun 30, 2018 | 3.39 Mn |
| Mar 31, 2018 | 4.49 Mn |